Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 162 | Copyright © February 2022
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.
Objectives: To assess patients' abil...
Read MoreEarly Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
February 2022 | Volume 21 | Issue 2 | Original Article | 122 | Copyright © February 2022
Background: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.
O...
Read MoreIntralesional Mode of Drug Administration in Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 186 | Copyright © February 2022
The use of various conventional systemic and topical therapies in psoriasis has resulted in various major and minor side effects. Hence, we need to switch to intralesional administration of antipsoria...
Read MoreTreatment of Nail Psoriasis
February 2022 | Volume 21 | Issue 2 | Original Article | 146 | Copyright © February 2022
Nail psoriasis has a considerable negative impact on the quality of life by limiting the patient’s household chores, professional activities and social interactions. Treatment for nail psoriasis...
Read MorePlatelet Count, Mean Platelet Volume, and Red Cell Distribution Width as Markers for Psoriasis Severity
February 2022 | Volume 21 | Issue 2 | Original Article | 156 | Copyright © February 2022
Background: Psoriasis is a chronic, inflammatory skin condition that is growing in prevalence globally. Routinely available options to assess psoriasis severity and progression are li...
Read MoreAn Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021
Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read MoreAn Overview of Biologics for Psoriasis
November 2021 | Volume 20 | Issue 11 | Features | 1246 | Copyright © November 2021
The use of biologics has revolutionized the treatment of psoriasis but choosing the right agent could be challenging. Currently, there are multiple biologic options, each with advantages and disadvant...
Read MoreSuccessful Treatment of Palmoplantar Pustulosis With Apremilast
November 2021 | Volume 20 | Issue 11 | Editorials | 1255 | Copyright © November 2021
Palmoplantar pustulosis (PPP) is a chronic, debilitating autoimmune skin disease characterized by the presence of recurrent neutrophilic pustules on acral surfaces. Although similarities exist, PPP is...
Read MoreBiological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
October 2021 | Volume 20 | Issue 10 | Original Article | 1063 | Copyright © October 2021
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We re...
Read MoreCharacteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database
October 2021 | Volume 20 | Issue 10 | Features | 1127 | Copyright © October 2021
Guselkumab is approved by the Food and Drug Administration for the treatment of moderate-to-severe plaque psoriasis. However, characteristics of patients initiating guselkumab in a real-world setting ...
Read MoreSustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
August 2021 | Volume 20 | Issue 8 | Original Article | 880 | Copyright © August 2021
Background: Long-term efficacy, safety, and quality of life with ixekizumab (IXE) through 5 years in UNCOVER-1 and UNCOVER-2 patients with baseline scalp, nail, or palmoplantar psoria...
Read MoreFixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area
August 2021 | Volume 20 | Issue 8 | Original Article | 829 | Copyright © August 2021
Introduction: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. F...
Read MoreSerious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2
August 2021 | Volume 20 | Issue 8 | Original Article | 855 | Copyright © August 2021
Background: Anti-interleukin (IL)-17 biologic agents used to treat psoriasis are associated with onset/exacerbation of inflammatory bowel disease (IBD). Objectives: To determine the incidence of IBD o...
Read MoreAntihistamines in Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 844 | Copyright © August 2021
Psoriasis is polygenic, interleukin (IL)-17 and IL-23 driven chronic relapsing inflammatory multisystem disease caused by a complex interplay of endogenous and environmental factors. The most common a...
Read MoreReview of Apremilast Combination Therapies in the Treatment of Moderate to Severe Psoriasis
August 2021 | Volume 20 | Issue 8 | Original Article | 837 | Copyright © August 2021
Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. Apremilast, an oral phosphodiesterase-4 inhibitor is approved by the Federal Drug Administration (FDA)...
Read MoreCalcipotriene Plus Betamethasone Dipropionate Foam for Mild Psoriasis: Pooled Results from Three Randomized Trials
August 2021 | Volume 20 | Issue 8 | Original Article | 822 | Copyright © August 2021
Background: Psoriasis vulgaris is not easy to manage, even when mild. Knowledge of the efficacy of most topical therapies in this population is limited.
Objective:Read MoreEfficacy of Topical Herbal Anti-inflammatory Treatment (HAT1) for Treating Psoriasis: An Investigator-Initiated Open Label Study
August 2021 | Volume 20 | Issue 8 | Editorials | 912 | Copyright © August 2021
Atopical botanical complex from a novel combination of phytochemicals, denoted as herbal anti-inflammatory treatment 1 (HAT1), was developed for topical treatment of psoriasis....
Read MoreNivolumab Induced Psoriasis Successfully Treated With Acitretin
August 2021 | Volume 20 | Issue 8 | Editorials | 911 | Copyright © August 2021
Immunotherapy is emerging as a promising alternative treatment for a variety of solid tumors. Its beneficial effects are mediated through hijacking the immune system to mount an anti-tumor response. O...
Read MoreFixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Patients With Skin of Color
July 2021 | Volume 20 | Issue 7 | Original Article | 744 | Copyright © July 2021
Background: Few studies have examined topical psoriasis therapies in patients with skin of color. Fixed-combination halobetasol propionate (0.01%) and tazarotene (0.045%) lotion (HP/T...
Read MoreSeeing the Treatment of Psoriasis in a New Light: A Novel Medical Device Utilizing Localized Coal Tar and Narrowband UVB for Targeted Treatment of Plaque Psoriasis
June 2021 | Volume 20 | Issue 6 | Features | 701 | Copyright © June 2021
Given the high costs of systemic psoriasis therapies, studies have also shown that phototherapy achieves significant cost savings by repla...
Read More